Capricor signals pivotal HOPE-3 data imminent as FDA review process advances for deramiocel [Seeking Alpha]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Seeking Alpha
CEO Linda Marbán highlighted the imminent top line readout from the HOPE-3 Phase III clinical study of deramiocel for Duchenne muscular dystrophy, stating this is "just weeks away from a major Quick Insights The HOPE-3 trial results are pivotal for determining the approval and commercialization prospects of deramiocel for Duchenne muscular dystrophy, with data expected within weeks. Capricor has operational manufacturing facilities, implemented quality systems, addressed regulatory items, and initiated physician and market access strategies for U.S. commercialization. Risks include HOPE-3 trial outcome uncertainty, sensitivity to FDA approval, review timelines, regulatory flexibility if certain endpoints are missed, cash burn management, and dependence on milestone payments. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Capricor Therapeutics (NASDAQ:CAPR) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CAPR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Capricor Therapeutics: A High Risk/High Reward Name [Seeking Alpha]Seeking Alpha
- Here's Why This Biotechnology Skyrocketed by 439% in December [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics (NASDAQ:CAPR) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CAPR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
CAPR
Earnings
- 11/10/25 - In-Line
CAPR
Sec Filings
- 1/7/26 - Form 4
- 1/7/26 - Form 4
- 1/7/26 - Form 4
- CAPR's page on the SEC website